Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Newhorizon,
The share price is where it is for a reason , nothing at all due to what people post on here. I for one welcome Albi's and all other reflective contributions that add value, balance and perspective.
The last few interviews since July, Justin has asked Dan about the Chinese payment and each time Dan says it close to being resolved. Until it is resolved that shadow hangs over us and all potential or actual investors. Maybe you want Justin to be silenced for asking the questions that are utmost in most investors minds at the moment.
Let's hope it is resolved quickly and the result is positive for the Company and shareholders but please don't deride others when it is the situation that is the problem.
If you listen to the most recent interview with Dan on last Monday (9th September) Justin again asks the question about the payment (roughly 14:25 into Podcast) and Dan makes the point that the NFX chairman met with the CEO of New Summit in London and that "they are very close to a resolution on it" .
He has been saying that for a while but presumably it is still rumbling on.
I just wish we new the full picture as to what they are seeking to resolve.
Hi Albi,
This is the link from CPI website confirming KSW as interim FD. It's dated April 2019
https://www.uk-cpi.com/news/cpi-strengthens-leadership-team-support-growth-strategy
I think you and quercusrobor are correct . Maybe he has too much on with being FD at CPI and if they are selling down their holdings he thought better to sever the ties.
Cheers
Dave
Because he was a Non-exec Director at NFX and abruptly resigned just before the AGM and he is (from April this year) an interim FD at CPI and they recently commenced been selling down some of there extensive holdings in NFX
It's just my own ramblings maybe but thought I'd air them.
It does seem strange that Kirk Siderman-Wolter resigned "abruptly" (according to Alliance news) and for "personal" reasons from the AGM attendees. I am wondering if there is a connection here between the Chinese involvement and whatever is happening behind the scenes and the sudden resignation of KSW and the sell down from CPI.
Remember that CPI is essentially funds derived from HM Gov and all the difficulties currently ongoing with the Chinese
Just a thought that's all.
Looks like whatever Dan's plan to smooth the dumping of CPI shares hasn't worked as yet anyway.
Seems like we will probably be quite a few cheap shares dumped on the market for the next few weeks.
Obviously this may be offset if we get any news on the Chinese payment / contract.
Anyone know how much CPI paid for the shares?
Cheers
Dave
I think that's total speculation and wouldn't buy into this. Dan knows the value of the company is NXP002, the jewel in the crown. Can't see him negotiating this away until the full value is known and there are several bidders?
Many thanks to Plum, Cdub and Investor for the summary report of AGM Proceedings
Somebody mentioned about the Cannabinoid having incredible potential. I suspect that this will be in the pain relief/anxiety/depression space where the maximum potential lies. Reports, seemingly every week come out highlighting the numbers addicted to opioids or on long term prescriptions for depression/anxiety. Dan mentioned recently (I think in the most recent podcast) about the Ebers milestone payments being geared more to the tail end of the agreement which I suspect will incorporate the phased medical testing of these which I am guessing will be prescribed pharmaceutical drugs.
Just my thoughts.
For any of the guys attendees yesterday, did anyone glean anything about NXP001 rest of world licensing? Is this also dependent on the Chinese?
Many thanks again for posting
Dave
Albi,
I would think Kirk Siderman Wolter had a conflict of interest so had to resign.
I would not think he could be a director at Nurformix (albeit Non-Exec) and an interim FD at CPI as this link from 18th April alludes to:
https://www.uk-cpi.com/search/results?q=Kirk+Siderman-Wolter
I'm not sure whether a Non-exec is party to sensitive information, but maybe when CPI started selling shares a couple of weeks ago I would have thought he needed to sever ties.
Of course, I could be completely wrong.
Albi,
No doubt you will label Dan as a ramper as he was very positive and to be fair most CEO's are when delivering their Companies news. That is part of their remit...to sell the company to investors and give a positive spin. Most investors will genuinely look at the positives as they have money invested but it is useful to show balance show a contrarian position is good and you cannot be hounded for that providing there is no ulterior motive and I don't believe you have.
In respect of the point you make about the payment, it is obviously still a concern but I am re-assured by the BOD and particularly their mitigation response as stated in the Annual Results on Page 20 where it states:
"The directors’ recognise that there are inherent material uncertainties asto when milestones in research will be achieved which will give a right to revenue and, as a consequence, the likely date of the related cash receipts. The directors have considered alternative strategies which include postponing uncommitted research expenditure, securing alternative licensing arrangements from those currently planned and utilising the Group’s established network of licensed brokers for fundraising. "
I agree that their is a risk but they have a mitigation strategy and I believe any necessity to fund raise will be a last resort.
Sorry forgot to add link
https://www.uk-cpi.com/news/cpi-strengthens-leadership-team-support-growth-strategy
Thanks Chris for the info.
It also appears that Kirk Siderman – Wolter who is Non executive director at Nuformix has recently joined CPI as Interim Finance Director.
CPI appears to be Government funded so does that make Nuformix partially nationalised (not like RBS ...hopefully!)
Really can't believe that on 24th August 2014, Intermune, the company that discovered and licensed Esbriet for Pulmonary fibrosis, was bought out for $8.3b by Roche. The drug now has sales of around $1b p.a
In NXP002 we have a drug that outperform Esbriet and can possibly be extended to other fibrotic conditions, yet we are sitting on a measly MCap of < £40m and that's just one of the programs and 1 condition.
Wow!
No wonder Dan says he is excited!
Mars1,
I agree that this could be huge. I saw a recent interview with Dan where he said they were particularly going after the pain relief and mental health markets. These are huge. He mentioned about the opioid market where so many are addicted to opium derivatives and mental heath conditions such as anxiety and depression again with so much of the population on drugs such as anti-depressants. Essentially, there is a mental health epidemic so this would be a fantastic market to make inroads into if they can get the right molecules.